Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

JNJ4796

😃Good
Catalog No. T15625Cas No. 2241664-16-2

JNJ4796 is an orally active fusion inhibitor of the influenza virus, inhibiting hemagglutinin (HA)-mediated fusion to neutralize the influenza A group 1 virus. JNJ4796 mimics the functionality of broadly neutralizing antibodies (bnAbs).

JNJ4796

JNJ4796

😃Good
Catalog No. T15625Cas No. 2241664-16-2
JNJ4796 is an orally active fusion inhibitor of the influenza virus, inhibiting hemagglutinin (HA)-mediated fusion to neutralize the influenza A group 1 virus. JNJ4796 mimics the functionality of broadly neutralizing antibodies (bnAbs).
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
25 mg$2,1208-10 weeks8-10 weeks
50 mg$2,7808-10 weeks8-10 weeks
100 mg$3,7008-10 weeks8-10 weeks
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Resource Download

Product Introduction

Bioactivity
Description
JNJ4796 is an orally active fusion inhibitor of the influenza virus, inhibiting hemagglutinin (HA)-mediated fusion to neutralize the influenza A group 1 virus. JNJ4796 mimics the functionality of broadly neutralizing antibodies (bnAbs).
Targets&IC50
H1/Bris:(EC50)12 nM, H5/Viet:3.24 μM(EC50), H1/Cal:66 nM(EC50), H1/PR8:22 nM(EC50), H1/SI06:13 nM(EC50), H5/H97:449 nM(EC50), H1/NCa:38 nM(EC50)
In vitro
The mechanism of action of JNJ4796 is demonstrated to be based on inhibition of the pH-sensitive conformational change of HA, like bnAb CR6261. That triggers the fusion of the viral and endosomal membranes and the release of the viral genome into the host cell[1].
In vivo
JNJ4796(50 and 10 mg/kg; twice daily) treatment, initiated one day before the challenge and continuing for 7 days, results in 100% survival at day 21 in comparison to the less potent compound JNJ8897 for which less than 50% survival is achieved. JNJ4796 (p.o.) protects mice from lethal challenge of 25 times the median lethal dose (LD50) of H1N1 A/Puerto Rico/8/1934 virus. Oral doses of JNJ4796 cause dose-dependent efficacy after a sublethal viral challenge (LD90), with twice-daily administration of 15 and 5 mg/kg of JNJ4796 giving rise to 100% survival[1].
Chemical Properties
Molecular Weight537.57
FormulaC28H27N9O3
Cas No.2241664-16-2
SmilesCC(=O)Nc1ccc2oc(nc2c1)-c1ccnc(c1)C(=O)N1CCN(CC1)[C@@H](c1nnn(C)n1)c1ccccc1
Relative Density.1.44 g/cm3 (Predicted)
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy JNJ4796 | purchase JNJ4796 | JNJ4796 cost | order JNJ4796 | JNJ4796 chemical structure | JNJ4796 in vivo | JNJ4796 in vitro | JNJ4796 formula | JNJ4796 molecular weight